News: Medicine

View:

1999

 

Found press releases

 

Althin Medical joins forces with Baxter

12/22/1999 10:18 AM EST  -   ALTHIN MEDICAL
- The Board recommends the offer

Baxter announced today a public offer to the shareholders of Althin
Medical to acquire their shares in the company. The Board of Directors of
Althin Medical recommends the shareholders to accept Baxter's offer.

Through its Swedish subsidiary, Baxter Sweden AB, Baxter International
Inc. has today announced a public offer to the shareholders of...

Monsanto and Pharmacia & Upjohn provide additional financial information relatin...

12/22/1999 3:27 AM EST  -   PHARMACIA & UPJOHN
MONSANTO AND PHARMACIA & UPJOHN PROVIDE ADDITIONAL FINANCIAL INFORMATION
RELATING TO COMPANIES' PLANNED MERGER

ST. LOUIS and PEAPACK, NJ (Dec. 22, 1999) - Monsanto Company (NYSE: MTC)
and Pharmacia & Upjohn (NYSE: PNU) today announced additional financial
details relating to the planned merger between the two companies.

The companies said that estimated full year 1999 sales of...

Exercise of Over-allotment Option

12/21/1999 10:16 AM EST  -   Q-Med
In connection with the recent offering of shares of Q-Med AB (publ), Aros
Securities has decided to exercise in full its over-allotment option to
purchase 1,000,000 shares in Q-Med.

The over-allotment option gives Aros Securities, on behalf of the
Managers, the right to purchase up to 500,000 shares from each of Agerup
Holding B.V. and HealthCap KB at a price of SEK 58 per...

Gambro divests French hospital

12/21/1999 6:03 AM EST  -   Gambro
Stockholm, Sweden - Gambro AB (Stockholm Stock Exchange: GAMBaST,
GAMBbST), a leading international medical technology and healthcare com-
pany, today announced that it has agreed to sell the French hospital
Résidence du Parc in Marseille to a subsidiary of the French group FD5.
The divestiture does not include the dialysis clinics operation which,
with its 315 patients, is one of the...

Repurchase of shares in AstraZeneca PLC

12/21/1999 4:21 AM EST  -   AstraZeneca
REPURCHASE OF SHARES IN ASTRAZENECA PLC

AstraZeneca PLC announces that on 20 December 1999, it purchased for
cancellation 1,000,000 ordinary shares of AstraZeneca PLC at a price of
2527 pence per share.

G H R Musker
Company Secretary

21 December 1999

AstraZeneca submits first regulatory application for Symbicort

12/15/1999 5:33 AM EST  -   AstraZeneca
ASTRAZENECA SUBMITS FIRST REGULATORY APPLICATION FOR ITS NEW ASTHMA
MEDICATION SYMBICORT VIA EUROPEAN MUTUAL RECOGNITION

AstraZeneca today announced that the regulatory application for Symbicort@
, budesonide and formoterol in a single inhaler (Turbuhaler@) for
maintenance therapy in asthma, has been submitted to the authorities in
Sweden as the first step in the European Union's...

Repurchase of shares in AstraZeneca PLC

12/15/1999 3:51 AM EST  -   AstraZeneca
REPURCHASE OF SHARES IN ASTRAZENECA PLC


AstraZeneca PLC announces that on 14 December 1999, it purchased for

cancellation 1,391,444 ordinary shares of AstraZeneca PLC at a price of
2584 pence per share.


G H R Musker
Company Secretary

15 December 1999

Biacore extends top management

12/14/1999 9:19 AM EST  -   Biacore
BIACORE EXTENDS TOP MANAGEMENT

Lars-Göran Andrén Appointed Executive Chairman


Biacore (SSE: BCOR; Nasdaq: BCOR) plans to further focus its business
towards markets with high growth potential, especially products for
research, development and other applications within the pharmaceutical
industry. In recent years it has become clear that Biacore's biosensor
technology...

Interim report, May 1, - October 31,1999/2000

12/14/1999 6:00 AM EST  -   Elekta
· An operating loss of SEK 37 M (loss: 43) was reported. Before items affecting comparability the operating loss was SEK 37 M (loss: 97).

· An operating profit of SEK 20 M was posted for the second quarter.

· Cash flow was positive for the fourth consecutive quarter.

· The sale of IGS and the related winding up measures is estimated to have a favorable impact in the order of SEK 20...

Gambro divests the Excorim immunoadsorption business

12/14/1999 3:04 AM EST  -   Gambro
Stockholm, Sweden - Gambro AB (Stockholm Stock Exchange: GAMBaST,
GAMBbST), a leading international medical technology and healthcare com-
pany, today announced that it has agreed to sell the Excorim immunoadsorp-
tion business to Fresenius Hemocare effective January 24, 2000. Excorim is
an operating unit of COBE BCT, a subsidiary of Gambro. In 1998 Excorim had
sales of about SEK 30 M (USD...